MorHap

MorHap is a heroin hapten. MorHap conjugated to tetanus toxoid (TT), palm-CV2, and to monophosphoryl lipid A (MPLA) -containing liposomes partially blocks heroin-induced analgesia and hyperlocomotion in mice. MorHap designed conjugates also significantly inhibits HIV-1 binding to α4β7 receptors. MorHap can be used in research to develop vaccines related to heroin addiction and HIV-1 infection[1].

Product Specifications

UNSPSC

12352005

Target

Integrin

Type

Reference compound

Related Pathways

Cytoskeleton

Applications

COVID-19-immunoregulation

Field of Research

Infection; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/morhap.html

Solubility

10 mM in DMSO

Smiles

OC1=C(O[C@H]2[C@H](NC(CCSC(C3=CC=CC=C3)(C4=CC=CC=C4)C5=CC=CC=C5)=O)C=C6)C([C@]2(CC7)[C@]6([H])C(N7C)C8)=C8C=C1

Molecular Formula

C39H38N2O3S

Molecular Weight

614.80

References & Citations

[1]Torres OB, et al. Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant. NPJ Vaccines. 2017 May 2;2:13.